The activation of the GPCR-mediated PI3K/Akt pathway is a recognized downstream event and a promising therapeutic target in neurodegenerative diseases such as Parkinson's (53) and Alzheimer's diseases (54). This evidence concerns the gene AKT1 and Parkinsonism.